PE20180316A1 - Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda - Google Patents
Compuestos piridopirimidinona y su uso como moduladores del receptor de nmdaInfo
- Publication number
- PE20180316A1 PE20180316A1 PE2017002006A PE2017002006A PE20180316A1 PE 20180316 A1 PE20180316 A1 PE 20180316A1 PE 2017002006 A PE2017002006 A PE 2017002006A PE 2017002006 A PE2017002006 A PE 2017002006A PE 20180316 A1 PE20180316 A1 PE 20180316A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrogen
- alkyl
- compounds
- modulators
- nmda receptor
- Prior art date
Links
- IAAQUOVTPAMQCR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-2-one Chemical class C1=CC=C2NC(=O)N=CC2=N1 IAAQUOVTPAMQCR-UHFFFAOYSA-N 0.000 title 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- -1 2 - [(N-ethyl-4-fluoro-anilino) methyl] pyrido [1,2-a] pyrimidin-4-one Chemical compound 0.000 abstract 1
- OLPHYKMWWHKMQS-UHFFFAOYSA-N 2-[(n-ethylanilino)methyl]-7-methylpyrido[1,2-a]pyrimidin-4-one Chemical compound C=1C(=O)N2C=C(C)C=CC2=NC=1CN(CC)C1=CC=CC=C1 OLPHYKMWWHKMQS-UHFFFAOYSA-N 0.000 abstract 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a compuestos de formula I: donde X es -Ar, -O-Ar, entre otros; R1 es Hidrogeno, halo, entre otros; R2 es alcoxi C1-C6, R3 hidrogeno, alquilo C1-C6, entre otros; R4 es hidrogeno o alquilo C1-C6; R5 es hidrogeno o alquilo C1-C6; R6 es hidrogeno o alquilo C1-C6. Son compuestos preferidos: 2-[(N-etilanilino)metil]-7-metil-pirido[1,2-a]pirimidin-4-ona ; 2-[(N-etil-4-fluoro-anilino)metil]pirido[1,2-a]pirimidin-4-ona, entre otros. Se proporciona ademas metodos de preparacion de los compuestos y la utilizacion como moduladores alostericos positivos de NR2A destinados al tratamiento de enfermedades y condiciones asociadas al SNC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015076617 | 2015-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180316A1 true PE20180316A1 (es) | 2018-02-09 |
Family
ID=55809078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002006A PE20180316A1 (es) | 2015-04-15 | 2016-04-12 | Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10280165B2 (es) |
| EP (1) | EP3283487B1 (es) |
| JP (2) | JP6847851B2 (es) |
| KR (1) | KR20170137137A (es) |
| CN (1) | CN107531696B (es) |
| AU (1) | AU2016248886B2 (es) |
| BR (1) | BR112017021083A2 (es) |
| CA (1) | CA2982217A1 (es) |
| CL (1) | CL2017002498A1 (es) |
| CO (1) | CO2017009989A2 (es) |
| CR (1) | CR20170462A (es) |
| IL (1) | IL254921B (es) |
| MX (1) | MX373162B (es) |
| PE (1) | PE20180316A1 (es) |
| PH (1) | PH12017501876A1 (es) |
| RU (1) | RU2717665C2 (es) |
| SG (1) | SG11201708294YA (es) |
| UA (1) | UA120647C2 (es) |
| WO (1) | WO2016166078A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3055315T3 (pl) | 2013-10-11 | 2018-12-31 | F. Hoffmann-La Roche Ag | Tiazolopirymidynony jako modulatory aktywności receptora nmda |
| AU2016248886B2 (en) | 2015-04-15 | 2020-09-10 | F. Hoffmann-La Roche Ag | Pyridopyrimidinones and their use as NMDA receptor modulators |
| PL3386591T3 (pl) | 2015-12-09 | 2021-02-22 | Novartis Ag | Heteroaromatyczne modulatory receptorów nmda i ich zastosowania |
| US11274107B2 (en) | 2016-12-22 | 2022-03-15 | Cadent Therapeutics, Inc. | NMDA receptor modulators and uses thereof |
| SG11202101125VA (en) | 2018-08-03 | 2021-03-30 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and uses thereof |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| JP7741100B2 (ja) | 2020-05-04 | 2025-09-17 | アムジェン インコーポレイテッド | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6951875B2 (en) * | 2001-10-29 | 2005-10-04 | Hoffmann-La Roche Inc. | Conjugated aromatic compounds with a pyridine substituent |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| CA2528771A1 (en) * | 2003-06-20 | 2004-12-29 | Chiron Corporation | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| AU2008213836A1 (en) * | 2007-02-05 | 2008-08-14 | Xenon Pharmaceuticals Inc. | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
| KR101811549B1 (ko) * | 2013-06-19 | 2017-12-26 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체 |
| PL3055315T3 (pl) * | 2013-10-11 | 2018-12-31 | F. Hoffmann-La Roche Ag | Tiazolopirymidynony jako modulatory aktywności receptora nmda |
| AU2016248886B2 (en) | 2015-04-15 | 2020-09-10 | F. Hoffmann-La Roche Ag | Pyridopyrimidinones and their use as NMDA receptor modulators |
-
2016
- 2016-04-12 AU AU2016248886A patent/AU2016248886B2/en not_active Ceased
- 2016-04-12 JP JP2017553877A patent/JP6847851B2/ja active Active
- 2016-04-12 RU RU2017139254A patent/RU2717665C2/ru active
- 2016-04-12 MX MX2017013101A patent/MX373162B/es active IP Right Grant
- 2016-04-12 CN CN201680021960.3A patent/CN107531696B/zh active Active
- 2016-04-12 BR BR112017021083-5A patent/BR112017021083A2/pt not_active IP Right Cessation
- 2016-04-12 SG SG11201708294YA patent/SG11201708294YA/en unknown
- 2016-04-12 KR KR1020177032061A patent/KR20170137137A/ko not_active Ceased
- 2016-04-12 CA CA2982217A patent/CA2982217A1/en not_active Abandoned
- 2016-04-12 WO PCT/EP2016/057962 patent/WO2016166078A1/en not_active Ceased
- 2016-04-12 CR CR20170462A patent/CR20170462A/es unknown
- 2016-04-12 UA UAA201711077A patent/UA120647C2/uk unknown
- 2016-04-12 PE PE2017002006A patent/PE20180316A1/es unknown
- 2016-04-12 EP EP16718618.8A patent/EP3283487B1/en active Active
-
2017
- 2017-09-29 CO CONC2017/0009989A patent/CO2017009989A2/es unknown
- 2017-10-03 CL CL2017002498A patent/CL2017002498A1/es unknown
- 2017-10-08 IL IL254921A patent/IL254921B/en active IP Right Grant
- 2017-10-13 PH PH12017501876A patent/PH12017501876A1/en unknown
- 2017-10-13 US US15/783,373 patent/US10280165B2/en active Active
-
2020
- 2020-12-03 JP JP2020200946A patent/JP2021046428A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN107531696A (zh) | 2018-01-02 |
| CO2017009989A2 (es) | 2018-01-05 |
| RU2017139254A3 (es) | 2019-09-30 |
| WO2016166078A1 (en) | 2016-10-20 |
| BR112017021083A2 (pt) | 2018-07-03 |
| KR20170137137A (ko) | 2017-12-12 |
| IL254921B (en) | 2021-02-28 |
| AU2016248886A1 (en) | 2017-10-12 |
| JP2018511627A (ja) | 2018-04-26 |
| CN107531696B (zh) | 2021-03-16 |
| JP2021046428A (ja) | 2021-03-25 |
| JP6847851B2 (ja) | 2021-03-24 |
| PH12017501876A1 (en) | 2018-02-26 |
| EP3283487B1 (en) | 2019-10-16 |
| IL254921A0 (en) | 2017-12-31 |
| HK1245259A1 (zh) | 2018-08-24 |
| SG11201708294YA (en) | 2017-11-29 |
| CA2982217A1 (en) | 2016-10-20 |
| EP3283487A1 (en) | 2018-02-21 |
| US10280165B2 (en) | 2019-05-07 |
| RU2717665C2 (ru) | 2020-03-24 |
| UA120647C2 (uk) | 2020-01-10 |
| MX2017013101A (es) | 2018-01-30 |
| RU2017139254A (ru) | 2019-05-15 |
| US20180127414A1 (en) | 2018-05-10 |
| AU2016248886B2 (en) | 2020-09-10 |
| CR20170462A (es) | 2018-02-01 |
| MX373162B (es) | 2020-04-21 |
| CL2017002498A1 (es) | 2018-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180316A1 (es) | Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda | |
| NI201400081A (es) | Nuevos derivados de indolizina , su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| UY36734A (es) | Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
| BR112016025423A2 (pt) | compostos e composições como agonistas de receptores do tipo toll 7 | |
| EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
| NZ629025A (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| CR20140336A (es) | Nuevos derivados de fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY35639A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| GT201500159A (es) | Derivados de imidazopiridazina como moduladores del receptor gabaa | |
| MY184433A (en) | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders | |
| UY35626A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| NZ723502A (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| MX2013012211A (es) | Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato. | |
| CO2017000980A2 (es) | Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a) | |
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| CO2019010804A2 (es) | Derivados de indol n–sustituidos | |
| CL2013003056A1 (es) | Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. | |
| SV2018005657A (es) | "nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen" | |
| MX2015014025A (es) | Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk. | |
| MX2016003422A (es) | Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen. | |
| UY33722A (es) | Oxazolidinonas como moduladores de mglur5 | |
| CO6531479A2 (es) | Derivados de espirolactama y uso de los mismos |